Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 13/20 | 0.71 |
| ▸ | FLT1 | P17948 | 5/20 | 0.71 |
| ▸ | KIT | P10721 | 3/20 | 0.71 |
| ▸ | ABL1 | P00519 | 2/20 | 0.71 |
| ▸ | CSF1R | P07333 | 2/20 | 0.71 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.71 |
| ▸ | FLT4 | P35916 | 2/20 | 0.71 |
| ▸ | EGFR | P00533 | 1/20 | 0.71 |
| ▸ | BRAF | P15056 | 1/20 | 0.64 |
| ▸ | IGF1R | P08069 | 1/20 | 0.62 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.62 |
| ▸ | TEK | Q02763 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | NAMPT | P43490 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4977961 | 0.92 | KDR (0.73) | KDRFLT1KITABL1CSF1R | |
| SCHEMBL1009989 | 0.90 | KDR (0.65) | KDRFLT1KITABL1CSF1R | |
| SCHEMBL3005186 | 0.90 | KDR (0.71) | KDRFLT1KITABL1CSF1R | |
| SCHEMBL30846489 | 0.90 | KDR (0.71) | KDRFLT1KITABL1CSF1R | |
| SCHEMBL4979677 | 0.90 | KDR (0.71) | KDRFLT1KITABL1CSF1R | |
| SCHEMBL4981514 | 0.89 | KDR (0.74) | KDRFLT1KITABL1CSF1R | |
| SCHEMBL27467101 | 0.89 | KDR (0.67) | KDRFLT1KITABL1CSF1R | |
| SCHEMBL4981221 | 0.87 | KDR (0.80) | KDRFLT1KITABL1CSF1R | |
| SCHEMBL4978550 | 0.87 | KDR (0.69) | KDRFLT1KITABL1CSF1R | |
| SCHEMBL4976779 | 0.86 | KDR (0.71) | KDRFLT1KITABL1CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040198782-A1 | N-aryl (THIO) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | ALTMANN KARL-HEINZ (CH) | 2004-10-07 | — | — | US | claimed |
| CN-1152014-C | N-aryl (thio) anthranilic acid amide derivatives, their prepn. and their use as VEGF receptor tyrosine kinase inhibitors | ��˹��ŵ�� | 2004-06-02 | — | — | CN | claimed |
| US-20030064992-A1 | N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | ALTMANN KARL-HEINZ (CH) | 2003-04-03 | — | — | US | claimed |
| US-6448277-B2 | ANTITUOR AGENTS, ANTICARCINOGENIC AGENTS | NOVARTIS AG (CH) | 2002-09-10 | — | — | US | claimed |
| US-20020019414-A1 | N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2002-02-14 | — | — | US | claimed |
| CN-1331680-A | N-aryl (thio) anthranilic acid amide derivatives, their prepn. and their use as VEGF receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2002-01-16 | — | — | CN | claimed |
| US-8034811-B2 | Hydroxamic acid esters and pharmaceutical use thereof | LEO PHARMA A/S (DK) | 2011-10-11 | — | — | US | disclosed |
| US-8034811-B2 | Hydroxamic acid esters and pharmaceutical use thereof | LEO PHARMA A/S (DK) | 2011-10-11 | — | — | US | disclosed |
| EP-1697312-B1 | HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA AS (DK) | 2011-07-20 | — | — | EP | disclosed |
| US-20080293696-A1 | 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080085902-A1 | Combination Of A Vegf Receptor Inhibitor Or With A Chemotherapeutic Agent | BOLD GUIDO | 2008-04-10 | — | — | US | disclosed |
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | LEO PHARMA A/S (DK) | 2007-10-18 | — | — | US | disclosed |
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | LEO PHARMA A/S (DK) | 2007-10-18 | — | — | US | disclosed |
| US-6878720-B2 | VEGF receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2005-04-12 | — | — | US | disclosed |
| US-20040198782-A1 | N-aryl (THIO) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | ALTMANN KARL-HEINZ (CH) | 2004-10-07 | — | — | US | disclosed |
| CN-1152014-C | N-aryl (thio) anthranilic acid amide derivatives, their prepn. and their use as VEGF receptor tyrosine kinase inhibitors | ��˹��ŵ�� | 2004-06-02 | — | — | CN | disclosed |
| US-20030064992-A1 | N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | ALTMANN KARL-HEINZ (CH) | 2003-04-03 | — | — | US | disclosed |
| US-6448277-B2 | ANTITUOR AGENTS, ANTICARCINOGENIC AGENTS | NOVARTIS AG (CH) | 2002-09-10 | — | — | US | disclosed |
| US-20020019414-A1 | N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2002-02-14 | — | — | US | disclosed |
| CN-1331680-A | N-aryl (thio) anthranilic acid amide derivatives, their prepn. and their use as VEGF receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2002-01-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085902-A1 | Combination Of A Vegf Receptor Inhibitor Or With A Chemotherapeutic Agent | VEGFA, FLT1, FLT4 | KDR 4/4885FLT1 2/4885KIT 95/4885 |
| US-20030064992-A1 | N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | AXL, TYRO3, NR2E3 | KDR 4/4885FLT1 6/4885KIT 1200/4885 |
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | F9, F12, HDAC9 | KDR 75/4885FLT1 19/4885KIT 406/4885 |
| US-20080293696-A1 | 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents | ABCC3, HCCS, ABCC2 | KDR 2408/4885FLT1 1541/4885KIT 2298/4885 |
| US-20020019414-A1 | N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | AXL, TYRO3, KDR | KDR 3/4885FLT1 6/4885KIT 1055/4885 |
| US-20040198782-A1 | N-aryl (THIO) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | AXL, TYRO3, NR2E3 | KDR 4/4885FLT1 6/4885KIT 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.